EVOMELA
PeakNDAINTRAVENOUSPOWDER
Approved
Mar 2016
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
1
Data completeness
5/8 — Partial
EVOMELA by Acrotech Biopharma is type. First approved in 2016.
Drug data last refreshed 4h ago · AI intelligence enriched 1mo ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
EVOMELA is an intravenous powder formulation of melphalan, a nitrogen mustard alkylating agent used primarily in hematologic malignancies and multiple myeloma. It works by binding to DNA and causing cross-linking, leading to cell death. The drug is indicated for patients undergoing high-dose chemotherapy followed by hematopoietic stem cell transplantation.
Peak7.2 years to LOE
Product is at peak commercial maturity with stable pricing; commercial team focus is likely on maximization and access optimization rather than growth expansion.
Mechanism of Action
type. As a result, its cytotoxicity appears to be related to the extent of its interstrand cross-linking with DNA, probably by binding at the N position of guanine. Like other bifunctional alkylating agents, it is active against both resting and rapidly dividing tumor cells.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (1)
Safety & Efficacy Study High Dose Evomela Injection for MA Conditioning in MM Patients With Autologous Transplantation
Started Dec 2012
61 enrolled
Multiple Myeloma
Career Relevance
Working on EVOMELA offers stable career positioning in a mature, niche oncology franchise with predictable revenue and limited disruption from competitive launches. However, the peak-lifecycle stage and absence of ongoing trials signal that career advancement opportunities are more limited compared to growth-stage products; roles emphasize commercial excellence, payer management, and preparation for LOE.
Brand Manager
Worked on EVOMELA at Acrotech Biopharma? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.